Martinsried/Munich May 21, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announces that Dr. Axel Mescheder has been appointed the new Executive Board Member for Research & Development. Dr. Mescheder, previously head of Clinical Research & Development at MediGene, will take over the position of Executive Board Member from Dr. Ulrich Delvos, who will be resigning from the firm by mutual amicable agreement with the Company. Dr. Mescheder is a medical specialist in pharmacology and toxicology and has more than 15 years of management experience in clinical research & development at international pharmaceutical and biotech companies.
